Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
- Trial name
- NCT05053035
- Testing
- AL001
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alector Inc.
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
Rehabilitation in SOD1 ALS Treated With Tofersen
The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program.
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease
- Trial name
- NCT05725759
- Testing
- Rehabilitation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Amyotrophic Lateral Sclerosis
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a global multicenter study designed to evaluate the safety and clinical effects of 4 oral doses of TCH346 (1.0, 2.5, 7.5, and 15 mg) compared to placebo in patients with mild or mild to moderate stages of ALS.
- Trial name
- NCT00072709
- Testing
- TCH346
- Where
- 9 sites in United States, Belgium and 7 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Study the cervical spinal cord and brain over time to assess changes and differences in subjects with amyotrophic lateral sclerosis.
- Trial name
- NCT02058732
- Testing
- MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
Exogenous Toxicants and Genetic Susceptibility in ALS
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members.
- Trial name
- NCT00011154
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
- Trial name
- ADORE (NCT05178810)
- Testing
- FAB122
- Where
- 38 sites in Belgium, France and 9 more
- Volunteers
- 313 people
- Sponsor
- Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis
Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)
The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.
- Trial name
- NCT00846560
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Amyotrophic Lateral Sclerosis, Dietary Habits
Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)
The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients complemented by the analysis of fatty acid distribution in erythrocyte lipids.
- Conditions
- Amyotrophic Lateral Sclerosis, Dietary Habits, Disorder of Fatty Acid Metabolism
- Trial name
- JERN_ALS (NCT02572479)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Jena
Amyotrophic Lateral Sclerosis
CNS10-NPC-GDNF for the Treatment of ALS
The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT02943850
- Testing
- Stem cell (HPC) implantation, Stereotactic surgical device
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cedars-Sinai Medical Center
Amyotrophic Lateral Sclerosis
RAPA-501 Therapy for ALS
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
- Trial name
- NCT04220190
- Testing
- RAPA-501 Autologous T stem cells
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rapa Therapeutics LLC
Amyotrophic Lateral Sclerosis
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.
- Trial name
- NCT03836716
- Testing
- Arimoclomol
- Where
- 23 sites in United States, Belgium and 9 more
- Volunteers
- 120 people
- Sponsor
- ZevraDenmark
Amyotrophic Lateral Sclerosis
Intermediate-Sized Expanded Access Study
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
- Trial name
- NCT05597436
- Testing
- Trehalose
- Where
- 21 sites in United States
- Sponsor
- Seelos Therapeutics, Inc.
Amyotrophic Lateral Sclerosis
Italian Validation of the Beaumont Behavioural Inventory (BBI)
Up to 50% of patients affected with amyotrophic lateral sclerosis (ALS) can show behavioral dysfunctions within the spectrum of frontotemporal degenerations (FTD) - namely, apathy, disinhibition, loss of sympathy/empathy…
- Trial name
- BBI (NCT04440644)
- Testing
- BBI
- Where
- Italy
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Amyotrophic Lateral Sclerosis (ALS)
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC).
- Trial name
- VITALS (NCT07454733)
- Testing
- Video recording, Notes Instruction
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Trustees of Dartmouth College
ALS
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
The primary objective of this study is to assess the safety and tolerability, with emphasis on the oral cavity, of ROSF (containing riluzole 50mg) in subjects with amyotrophic lateral sclerosis (ALS) administered twice daily for…
- Trial name
- NCT03457753
- Testing
- Riluzole Oral Soluble Film
- Where
- United States
- Sponsor
- Aquestive Therapeutics
Amyotrophic Lateral Sclerosis (ALS)
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
This study will evaluate the safety and efficacy of repeated administration of NurOwn® (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are…
- Trial name
- NCT03280056
- Testing
- NurOwn® (MSC-NTF cells), Bone Marrow aspiration
- Where
- 6 sites in United States
- Volunteers
- 196 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II)
This study will try to understand the difference in brain structure between ALS patients and healthy people of similar age. ALS is a condition affecting the nervous system with disruption of the brain networks.
- Trial name
- CoALS-II (NCT05404867)
- Testing
- fMRI
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Amyotrophic Lateral Sclerosis
Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)
The investigators want to test feasibility of a structured program of telesurveillance and home cough assistance for ALS patients.
- Trial name
- NCT00613899
- Testing
- telesurveillance
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Salvatore Maugeri
Amyotrophic Lateral Sclerosis
Nocturnal PtcCO2 Monitoring in Patients With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motoneurons, with a prevalence around 5/100.000. Respiratory muscle involvement is a major feature in ALS and remains the main prognostic factor.
- Trial name
- NCT00879593
- Testing
- PtcCO2
- Where
- 2 sites in France
- Volunteers
- 66 people
- Sponsor
- Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche